Dose-Reduced Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation for Human Immunodeficiency Virus-Associated Lymphoma: AIDS Malignancy Consortium Study 020

Biology of Blood and Marrow Transplantation

Volumn 14, Issue 1, 2008, Pages 59-66

  Spitzer, Thomas R ^a   Ambinder, Richard F ^g   Lee, Jeannette Y ^b   Kaplan, Lawrence D ^c   Wachsman, William ^d   Straus, David J ^e   Aboulafia, David M ^f   Scadden, David T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Mason Medical Center   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired immunodeficiency syndrome; Autologous stem cell transplantation; Busulfan; Cyclophosphamide; Lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; ATOVAQUONE; BUSULFAN; CD4 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAPSONE; DEFIBROTIDE; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; MESNA; NUCLEOSIDE ANALOG; PHENYTOIN; PROTEINASE INHIBITOR;

ADULT; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BACTEREMIA; BLEEDING; BRAIN DISEASE; BURKITT LYMPHOMA; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FOLLOW UP; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERURICEMIA; HYPOPHOSPHATEMIA; LEUKAPHERESIS; LIVER VENOOCCLUSIVE DISEASE; LYMPHOCYTE COUNT; MALE; MENTAL HEALTH; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA AND VOMITING; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PAIN; PATIENT SELECTION; PHARYNGITIS; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PROBABILITY; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; STOMATITIS; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, AIDS-RELATED; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 37349107187     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.03.014     Document Type: Article

References (34)

1. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 323 (1995) 1540-1545
2. Lin T.S., and Copelan E.A. Autologous stem cell transplantation for non-Hodgkin's lymphoma. Curr Hematol Rep 2 (2003) 310-315
3. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (2002) 2065-2071
4. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341 (1993) 1051-1054
5. Navarro W.H., and Kaplan L.D. AIDS-related lymphoproliferative disease. Blood 107 (2006) 13-20
6. Clayton A., and Mughal T. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy in the post-highly active antiretroviral therapy era?. Hematol Oncol 22 (2004) 111-120
7. Bower M., Gazzard B., Mandalia S., et al. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy. Ann Intern Med 143 (2005) 265-273
8. Mounier N., Spina M., Gabarre J., et al. AIDS-related non-Hodgkin's lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood 107 (2006) 3832-3840
9. Spina M., Gabarre J., Rossi G., et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 100 (2002) 1984-1988
10. Weiss R., Mitrou P., Arasteh K., et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival. Results of the German Multicenter Trial. Cancer 106 (2006) 1560-1568
11. Lim S.T., and Levine A.M. Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep 2 (2005) 146-153
12. Straus D.J. HIV-associated lymphoma: promising new results, but with toxicity. Blood 105 (2005) 1842
13. Krishnan A., Molina A., Zaia J., et al. Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas. Blood 105 (2005) 874-878
14. Serrano D., Carrion R., Balsalobre P., et al. HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 33 (2005) 487-494
15. Gabarre J., Marcelin A.G., Azar N., et al. High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease. Haematologica 89 (2004) 1100-1108
16. Re A., Cattaneo C., Michieli M., et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy. J Clin Oncol 21 (2003) 4423-4427
17. Wood C., and Harrington Jr. W. AIDS and associated malignancies. Cell Res 15 (2005) 947-952
18. Spitzer T.R., Cox B., Sepe P., et al. Dose adjusted busulfan/cyclophosphamide and autologous stem cell transplantation for recurrent lymphoma. Blood 104 (2004) 522a
19. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
20. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
21. Benicchi T., Ghidini C., Re A., et al. T-cell immune reconstitution after hematopoietic stem cell transplantation for HIV-associated lymphoma. Transplantation 80 (2005) 673-682
22. Santos G.W., Tutschka P.J., Brookmeyer R., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309 (1983) 1347-1353
23. Santos G.W. The development of busulfan/cyclophosphamide preparative regimens. Semin Oncol 20 (1993) 12-17
24. Grochow L.B., Jones R.J., Brundrett R.B., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 25 (1989) 55-61
25. Slattery J.T., Clift R.A., Buckner C.D., et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89 (1997) 3055-3060
26. Olavarria E., Hassan M., Eades A., et al. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation. Leukemia 14 (2000) 1954-1959
27. Kashyap A., Wingard J., Cagnoni P., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 8 (2002) 493-500
28. Lee J.H., Choi S.J., Kim S.E., et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 84 (2005) 321-330
29. Andersson B.S., Madden T., Tran H.T., et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 6 (2000) 548-554
30. Kiss T.L., Panzarella T., Messner H.A., et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 31 (2003) 73-78
31. de Magalhaes-Silverman M., Lister J., Rybka W., et al. Busulfan and cyclophosphamide (BU/CY2) as preparative regimen for patients with lymphoma. Bone Marrow Transplant 19 (1997) 777-781
32. Avalos B.R., Klein J.L., Kapoor N., et al. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY. Bone Marrow Transplant 12 (1993) 133-138
33. Vose J.M., Rizzo D.J., Tao-Wu J., et al. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant 10 (2004) 116-127
34. Lazarus H.M., Loberiza Jr. F.R., Zhang M.J., et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 27 (2001) 387-396